Literature DB >> 8814892

Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission.

J P Sieb1, M Milone, A G Engel.   

Abstract

The quinoline derivatives quinine, its stereoisomer quinidine, and chloroquine may worsen or provoke disorders of neuromuscular transmission. In this study, we investigate effects of these drugs on neuromuscular transmission by conventional microelectrode as well as patch-clamp techniques. At 5 x 10(-5) M, quinine, quinidine, and chloroquine reduced the quantal content of the end-plate potential by 37-45%. Between 10(-6) and 10(-4) M, all 3 drugs progressively decreased the amplitude and decay time constant of miniature end-plate potential (MEPP) and miniature end-plate current (MEPC); at 5 x 10(-3) M, the MEPP became undetectable. The effect on the MEPP was not reversed by 1 microgram/mL neostigmine. Single-channel patch-clamp analysis of the effects of quinine showed that this agent causes a long-lived open-channel as well as a closed-channel block of AChR. Tests for competitive inhibition or desensitization of the acetylcholine receptor (AChR) by quinine in concentrations that had a marked effect on the MEPC and on single-channel open and closed intervals were negative. Because quinoline drugs adversely affect both presynaptic and postsynaptic aspects of neuromuscular transmission at concentrations close to those employed in clinical practice, they should not be used, or used with caution, in disorders that compromise the safety margin of neuromuscular transmission.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814892     DOI: 10.1016/0006-8993(95)01349-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  Antibiotic-induced neurotoxicity.

Authors:  Shamik Bhattacharyya; Ryan Darby; Aaron L Berkowitz
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

Review 2.  The 5-HT3 receptor as a therapeutic target.

Authors:  Andrew J Thompson; Sarah C R Lummis
Journal:  Expert Opin Ther Targets       Date:  2007-04       Impact factor: 6.902

3.  Imprinted gene expression in fetal growth and development.

Authors:  L Lambertini; C J Marsit; P Sharma; M Maccani; Y Ma; J Hu; J Chen
Journal:  Placenta       Date:  2012-03-31       Impact factor: 3.481

Review 4.  Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.

Authors:  S Christopher Jones; Alfred Sorbello; Robert M Boucher
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

Review 5.  [Myasthenia gravis and myasthenic syndromes].

Authors:  W Marouf; J P Sieb
Journal:  Z Rheumatol       Date:  2009-08       Impact factor: 1.372

6.  Nicotinic acetylcholine currents of cultured Kkenyon cells from the mushroom bodies of the honey bee Aapis mellifera.

Authors:  F Goldberg; B Grünewald; H Rosenboom; R Menzel
Journal:  J Physiol       Date:  1999-02-01       Impact factor: 5.182

7.  The antimalarial drugs quinine, chloroquine and mefloquine are antagonists at 5-HT3 receptors.

Authors:  A J Thompson; M Lochner; S C R Lummis
Journal:  Br J Pharmacol       Date:  2007-05-14       Impact factor: 8.739

Review 8.  Decoding pathogenesis of slow-channel congenital myasthenic syndromes using recombinant expression and mice models.

Authors:  José David Otero-Cruz; Carlos Alberto Báez-Pagán; Luisamari Dorna-Pérez; Gary Emanuel Grajales-Reyes; Rosaura Teresa Ramírez-Ordoñez; Carlos A Luciano; Christopher Manuel Gómez; José Antonio Lasalde-Dominicci
Journal:  P R Health Sci J       Date:  2010-03       Impact factor: 0.705

9.  Antimalarial drugs inhibit human 5-HT(3) and GABA(A) but not GABA(C) receptors.

Authors:  A J Thompson; S C R Lummis
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

10.  Ultrasound: An ode to perioperative complicated malaria.

Authors:  Sukhen Samanta; Sujay Samanta; Kajal Jain; Bireswar Sinha; Rudrashish Haldar
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2015 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.